Wed, May 14, 9:04 PM (40 days ago)
**Enveric Biosciences, Inc. (ENVB) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No revenue generated, as Enveric is a research and development company. - **Profit Margins:** Negative, with a net loss of $2,184,966 for Q1 2025. - **Cash Flow:** Negative operating cash flow of $2,391,582 for Q1 2025, offset by positive financing cash flow of $4,448,914. - **Earnings Changes:** Net loss decreased by $271,949 compared to Q1 2024. - **Cash Position:** $4,294,435 in cash as of March 31, 2025, but insufficient for 12-month operating needs. **Operational Performance:** - **Expenses:** Total operating expenses decreased by $289,784 (12%) to $2,187,533 in Q1 2025. - General and administrative expenses decreased by $525,615 (28%). - Research and development expenses increased by $240,216 (47%). - **Stock Performance:** 1-for-15 reverse stock split effective January 27, 2025. - **Fundraising:** Completed a public offering in January 2025, raising approximately $4.2 million. **Trends and Uncertainties:** - **Going Concern:** Substantial doubt about the company's ability to continue as a going concern for the next year. - **Liquidity:** Insufficient cash on hand to meet 12-month operating needs. - **Future Operations:** Plans to raise additional capital through equity or debt financings and collaborations. **Future Impact:** - **Development Focus:** Primary focus on developing EB-003 in the EVM301 Series. - **Pipeline:** Unveiled EVM401 Series to broaden pipeline and target addiction and neuropsychiatric disorders. - **Licensing:** Out-licensed EVM201 Series to MycoMedica Life Sciences for further development and commercialization. **Key Metrics:** - **Cash Burn:** $2,391,582 in operating cash outflows for Q1 2025. - **Cash Position:** $4,294,435 in cash as of March 31, 2025. - **Working Capital:** $3,650,434 as of March 31, 2025. - **Accumulated Deficit:** $108,259,471 as of March 31, 2025. **Conclusion:** Enveric Biosciences faces significant financial challenges, with substantial doubt about its ability to continue as a going concern. The company is focused on developing its lead drug candidate, EB-003, and broadening its pipeline while seeking additional financing to support its operations.